Current Study
MASH | SF-CSP-002
The purpose of this study is to test the effectiveness and safety of the investigational medication in the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in at risk adults. This is a randomized, double-blind, placebo controlled and parallel group study of GL0034 (Utreglutide) for the treatment of (MASH).
Study Status
Recruiting
Duration
34 weeks
Clinic Visits
41
Phone Check-ins
1
Study Overview
Location
Spearwood, Osborne Park and Mandurah
Phase
2a
Study Duration
34 weeks
Main Entry Criteria
- 18 to 75 years of age
- BMI ≥ 30.0 kg  and ≤ 50 kg
- Liver fat content ≥ 8.5%
Main Exclusion Criteria
Assessments
- Medical and family history, including medicines, vitamins, and herbal supplements you takeÂ
- Vital signs like blood pressure, temperature, and pulse rate Â
- Height, weight, waist circumference, and physical examination Â
- Blood draws and urine collection for laboratory tests, Â
- Electrocardiogram (ECG)Â Â
- Magnetic resonance Imaging (MRI)Â Â
- FibroScan Â
At a Glance
Clinic Visits
41
Phone Calls
1
Duration
34 weeks